12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eteplirsen: Additional Phase IIb data

Additional data from 10 patients aged 7-13 with DMD in the modified intent-to-treat (mITT) population of the open-label Study 4658-US-202 extension of the double-blind, U.S. Phase IIb Study 4658-US-201 trial showed that patients who received either dose of eteplirsen for 74 weeks (30 or 50 mg/kg) had a 2.2 m reduction in mean 6MWT from baseline to week 74 compared to a 64.6 m reduction for patients who received placebo for 24 weeks followed by eteplirsen for an additional 50 weeks (p<=0.007). Mean baseline 6MWT scores were 388.6 m for the eteplirsen treatment group and 380.3 m for the placebo/delayed eteplirsen treatment group. Additionally, Sarepta said that patients in the placebo/delayed eteplirsen treatment...

Read the full 542 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >